Almac, a pharmaceutical business located in Northern Ireland, has announced plans to hire 1,800 people over the next three years.
More than 1,000 of them will be stationed in Northern Ireland.
Almac, which develops its own medications, employs over 6,000 people across its global operations, making it one of Northern Ireland's top employers.
Manufacturing and executing testing for large worldwide corporations is a significant element of its business.
Last year, the company, which is situated in Craigavon, County Armagh, was involved in the clinical trials of Pfizer and BioNTech's first effective Covid-19 vaccine.
BioNTech received clinical trial help from the firm's clinical services section in areas such as distribution, labeling, and temperature management.
"As demand for our services grows, our goal is to continue to build our worldwide workforce by aggressively hiring 1,800 new professionals across a wide variety of diverse and fascinating sectors," stated Alan Armstrong, CEO of Almac Group.
Operational, supervisory, and managerial positions are among the new positions. Almac is one of the few truly worldwide success stories to emerge from Northern Ireland.
Sir Allen McClay, the firm's late founder, was responsible for a substantial part of this.
His legacy carries on in the peculiar ownership structure of the firm, which is owned by the McClay Foundation charity trust.
Because of this structure, the company must constantly reinvest its revenues and be safeguarded from acquisition, allowing it to stay true to its Northern Irish heritage.
Almac has substantial facilities in the Republic of Ireland, England, and the United States, in addition to its operations in Northern Ireland.
It improved its pre-tax profit by 33% to £63.5 million in 2020, citing license fees from in-house goods as a boost to performance.
Turnover climbed by 6%, from £634 million to £677 million.
